Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The role of tumor necrosis factor-alpha as an upstream modulator of poor outcome in experimental subarachnoid hemorrhage.
EF 2012-13
Résumé
Subarachnoid hemorrhage comprises about 7% of all stroke. The spontaneous form is usually due to an aneurysmal rupture. Despite its relative rarity, it has garnered significant attention in the scientific community because it affects young people and there is a particularly poor outcome. Much of the mortality and poor outcome stems from a secondary stroke phenomenon that arises 3-14 days after ictus, called delayed cerebral ischemia (DCI). Although the pathogenesis is unclear, it is believed that a combination of large artery vasospasm, autoregulatory failure and local microthrombus formation contribute to the ischemia. Our research focuses on identifying pathogenetic factors that are both upstream and common mediators of these processes. Our research points to the inflammatory cytokine tumor necrosis factor alpha (TNF-a) to be such a target. To date, we have found that reducing TNF-a, either genetically or pharmacologically, in a mouse model of subarachnoid hemorrhage is able to decrease large intracranial vessel spasm, restore autoregulatory function to extraparenchymal resistance arteries and reduce neuronal apoptosis. Our current goal is to determine whether these changes extend to parenchymal arterioles, using in-vivo microscopy technique and within brain slices. Secondly, we will investigate the role of TNF-a in microthrombi generation, in accordance with the large body of data that shows a bidirectional relationship between coagulatory pathways and inflammation. This will be investigated by determining adhesion molecule expression using western blot, immunohistochemistry and in situ hybridization. Finally, we will determine if commercially-available TNF-a inhibitors reduce the consequences of DCI, thus setting the stage for human clinical trials. We hope that this work will provide more support for the role of TNF-a in mediating the secondary complications after SAH and provide compelling evidence to begin a phase I dose finding trial in human SAH subjects.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
279450
Name
Wan Hoyee
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The role of tumor necrosis factor-alpha as an upstream modulator of poor outcome in experimental subarachnoid hemorrhage.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Delayed Cerebral Ischemia; Subarachnoid Hemorrhage; Tumor Necrosis Factor Alpha
Abstract
Subarachnoid hemorrhage comprises about 7% of all stroke. The spontaneous form is usually due to an aneurysmal rupture. Despite its relative rarity, it has garnered significant attention in the scientific community because it affects young people and there is a particularly poor outcome. Much of the mortality and poor outcome stems from a secondary stroke phenomenon that arises 3-14 days after ictus, called delayed cerebral ischemia (DCI). Although the pathogenesis is unclear, it is believed that a combination of large artery vasospasm, autoregulatory failure and local microthrombus formation contribute to the ischemia. Our research focuses on identifying pathogenetic factors that are both upstream and common mediators of these processes. Our research points to the inflammatory cytokine tumor necrosis factor alpha (TNF-a) to be such a target. To date, we have found that reducing TNF-a, either genetically or pharmacologically, in a mouse model of subarachnoid hemorrhage is able to decrease large intracranial vessel spasm, restore autoregulatory function to extraparenchymal resistance arteries and reduce neuronal apoptosis. Our current goal is to determine whether these changes extend to parenchymal arterioles, using in-vivo microscopy technique and within brain slices. Secondly, we will investigate the role of TNF-a in microthrombi generation, in accordance with the large body of data that shows a bidirectional relationship between coagulatory pathways and inflammation. This will be investigated by determining adhesion molecule expression using western blot, immunohistochemistry and in situ hybridization. Finally, we will determine if commercially-available TNF-a inhibitors reduce the consequences of DCI, thus setting the stage for human clinical trials. We hope that this work will provide more support for the role of TNF-a in mediating the secondary complications after SAH and provide compelling evidence to begin a phase I dose finding trial in human SAH subjects.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wan, Hoyee
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~